Kexing Biopharm Unveils New Opportunities for Global Partnerships at CPHI Milan 2026

From October 6th to 8th, 2026, Kexing Biopharm showcased its impressive global pipeline of innovative medicines at the CPHI event in Milan. The company, listed on the Shanghai Stock Exchange as 688136.SH, utilized this platform to enhance its recognition among international buyers, biotech enterprises, and industry partners.

During the event, Kexing Biopharm presented a wide array of products, including co-developed biosimilars and the potential of over 30 products aimed at overseas markets. Their strategic focus spans therapeutic areas such as oncology, autoimmune diseases, and metabolic disorders. Kexing's marketing network significantly extends across approximately 70 countries, with nearly 200 registration applications submitted internationally.

Among the showcased products, Kexing's core offering, albumin-bound paclitaxel, has already been approved and commercialized in the European Union, United Kingdom, and other regions. This product is a key element of Kexing's strategy to address unmet clinical needs and capitalize on market potential. Furthermore, the company has ambitious plans to develop more than ten high-quality biosimilars for global markets, reflecting their commitment to innovation and quality.

To bolster its local presence in Europe, Kexing Biopharm has established a subsidiary in Germany and is progressing towards setting up additional branches in France, Spain, Italy, the United Kingdom, and the Netherlands. This localized approach allows Kexing Biopharm to more effectively meet regional customer needs and forge long-lasting partnerships. Their participation in CPHI and successive European events has provided a significant opportunity to deepen connections with local industry players.

The company's strategic direction, encapsulated by the theme of "Innovation + Internationalization," indicates its forward-thinking approach. Kexing's pipeline includes cutting-edge research in cancer cachexia, ophthalmic medicines, systemic lupus erythematosus (SLE), and inflammatory bowel diseases (IBD), which garnered significant interest at the expo. These initiatives are poised to target long-term solutions for chronic conditions and address various unmet clinical needs globally.

Quality remains the foundational pillar for Kexing's expanding global footprint. With 30 years of experience in industrial-scale biopharmaceutical production, Kexing boasts mature production and quality management systems. The production line for albumin-bound paclitaxel has received EU-GMP certification and is already approved in over 40 countries and regions, underpinning Kexing's commitment to excellence.

As Kexing Biopharm moves forward, the company remains dedicated to the innovation and commercialization of high-quality medicines. Collaborating with partners worldwide, Kexing aims to contribute significantly to improving health outcomes globally, revealing the impactful growth trajectory in the biopharmaceutical landscape.